Mariflora Forte Capsules

Each capsule contains 10 billion active bacterial strains:
Lactobacillus acidophilus 2.0 billion cfu
Lactobacillus rhamnosus 1.5 billion cfu
Saccharomyces boulardii 2.0 billion cfu
Lactobacillus plantarum 1.5 billion cfu
Lactobacillus casei 1.0 billion cfu
Bifidobacterium longum 1.0 billion cfu
Lactobacillus reuteri 1.0 billion cfu

Mariflora Forte is indicated for:

  • Prevention and treatment of diarrhoea in infants, children and adults.
  • Digestive disorders caused by imbalance of intestinal microflora like: Viral and bacterial infections of the gastrointestinal tract of infants, children and adults (e.g. rotavirus infection, traveller’s diarrhoea), Diarrhoea associated with antibiotics and irradiation at abdominal & pelvic organs.

It is also used in Irritable bowel syndrome (IBS), Inflammatory bowel disease (IBD), H. Pylori infections, Clostridium difficile infections, Crohn’s disease, ulcerative colitis, gastroenteritis and for the Prevention of HIV – associated diarrhoea.

Mariflora Forte contains freeze-dried Lactic acid bacteria, yeast and Bifidobacteria, which regulate the physiological balance of the intestinal microflora by producing organic compounds. These organic compounds include Lactic acid, hydrogen peroxide and Acetic acid that increase the acidity of intestine and curb the reproduction of many harmful bacteria. Lactic acid bacteria are naturally produced in small and large intestine and are involved in maintaining balance which is necessary for normal function of digestive enzymes.

  • Lactobacillus acidophilus strain reaches the intestine without being damaged by gastric acid and bile salts which are expected at meal times. After reaching intestine they colonise, support immune cells and create a healthy Lactic acid environment that limits survival of harmful bacteria. Lactobacillus acidophilus bacteria thrive in acidic environments and produces enzymes that create an unfavourable condition for other microorganisms to survive. It works in small intestine by out-competing other microorganisms (e.g. E.coli) for nutrients they rely on. They also produce lactase, an enzyme that helps in digestion of fats, proteins and dairy products, thus reduce the sensitivity of lactose. Furthermore, the bacteria have the ability to metabolize cholesterol and thus reduce the potential risk for coronary heart disease.
  • Lactobacillus rhamnosus bacteria exist naturally in the body, primarily in the intestine. These bacteria maintain a balance of “good bacteria” needed to prevent the growth of harmful bacteria in the stomach and intestine. Lactobacillus rhamnosus has been used to treat or prevent diarrhoea caused by rotavirus and other viral illnesses in babies and children. This product has also been used to treat diarrhoea that can occur while taking antibiotics.
  • Saccharomyces boulardii is non-colonizing, non-systemic yeast. It secretes enzymatic proteins, including a protease that degrades Clostridium difficile toxins and a phosphatase that inactivates endotoxins such as the lipopolysaccharide produced by E. coli. It also strengthens tight junctions between enterocytes (reducing chloride secretion), promotes maturation of the intestinal brush border membrane and stimulates production of glycoproteins (including secretory IgA). S. boulardii also promotes production of disaccharidases such as lactase, sucrase, maltase and N-aminopeptidase in the brush border allowing increased carbohydrate degradation and absorption in patients with diarrhoea and restores normal levels of short chain fatty acids in the colon which are necessary for absorption of water and electrolytes. In addition, S. boulardii may reduce inflammation in the GI tract by stimulating regulatory T cells and inhibiting mitogen-activating protein (MAP) kinase and nuclear factor-kappa B (NF-κB) signal transduction pathways, resulting in decreased secretion of interleukin (IL-8) and tumour necrosis factor alpha (TNFα). S boulardii also decreases inducible nitric oxide synthase (NOS) activity and up-regulates peroxisome proliferator-activated receptor-gamma (PPAR-γ), leading to a reduction in intestinal inflammation
  • Lactobacillus plantarum has shown to be an effective treatment for Irritable bowel syndrome (IBS), Crohn’s disease and Colitis. It has the ability to destroy pathogens and to preserve critical nutrients, vitamins and antioxidants. It has also shown the rare ability to produce L. lysine, a beneficial amino acid. Lactobacillus plantarum delivers therapeutic compounds and proteins to the body. The area of this research using the bacteria is new and ongoing.
  • Lactobacillus casei prevents an overpopulation of ingested lactic acid bacteria in gastrointestinal tract.
  • Lactobacillus casei reduces diarrhoea and helps in modification of micro flora in the body.
  • Bifidobacterium longum colonise primarily in large intestine (or colon). Here they promote the production of antibodies, support the body against toxins and inhibit the development of undesirable bacteria by competitively blocking their attachment to the intestinal wall lining.
  • Lactobacillus reuteri improves the host’s intestinal microbial balance and beneficially modulates the host’s mucosal immune response. It has antimicrobial activity against certain pathogenic bacteria as well as yeasts, fungi, protozoa and viruses. It reduces the frequency of diarrhoea in acute rotavirus gastroenteritis, duration of gastroenteritis, incidence of gastrointestinal and common infection, IgE-associated eczema in infants whose mothers had allergies, density of H. pylori bacteria, incidence of crying in colicky babies and frequency and intensity of antibiotic associated side-effects. It also decreases the aggravation of eczema or itching in children despite continuous intake of cow’s milk.

The effectiveness of probiotics is related to their ability to survive in the acidic environment of stomach and the alkaline conditions in the duodenum, as well as their ability to adhere to the intestinal mucosa of the colon and to colonize the colon. After passage through the stomach and the small intestine, those probiotics that do survive become established transiently in the colon.

Mariflora Forte is contraindicated in patients with known hypersensitivity to milk proteins.

Side effects are usually mild and most often include digestive disorder such as: intestinal gas or bloating. Symptoms of side effects, if any should subside after discontinuing the medicine. If symptoms persist, consult the physician.


  • Adults & Children above 12 years: 1 capsule one to three times a day.
  • Children 2 to 12 years: 1 capsule twice a day.
  • Infants and Children upto 2 years: 1 capsule once a day.

Store in a cool, dark & dry place. Keep out of reach of children.

10 capsules are packed in a alu alu blister and such 1 blister packed in a carton with insert.